Literature DB >> 27296314

Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis.

Roberto Giulio Romanelli, Cristina Stasi1.   

Abstract

Cirrhosis is a diffuse pathophysiological state of the liver considered to be the final stage of various liver injuries, characterized by chronic necroinflammatory and fibrogenetic processes, with subsequent conversion of normal liver architecture into structurally abnormal nodules, dense fibrotic septa, concomitant parenchymal exaustment and collapse of the liver tissue. Alcoholic liver disease and chronic infections due to HBV and/or HCV constitute the main causes of liver cirrhosis worldwide. During a lag time of 15 to 30 years, chronic liver diseases can lead to liver cirrhosis and its complications. Active hepatic inflammation plays a pivotal role in the inflammation- necrosis-regeneration process, which eventually leads to liver cirrhosis and hepatocellular carcinoma. Prognosis of liver cirrhosis is highly variable and influenced by several variables, such as etiology, severity of liver disease, presence of complications and comorbidities. In advanced cirrhosis, survival decreases to one or two years. Correct advanced diagnosis and selected treatment with different molecules may help in understanding mechanisms of fibrogenesis, the driving forces of cirrhosis's pathogenesis, and the scrupulous approach to more effective therapeutic procedures. Prevention of fibrosis with further deterioration of liver function through specific treatments is always required, through the removal of the underlying causes of liver disease. Advanced liver disease, with subsequent complications, requires targeted treatment. Therefore, the aim of this review is to assess the diagnosis and treatment of liver cirrhosis on the pathophysiological bases, searching for relevant studies published in English using the PubMed database from 2011 to the present.

Entities:  

Mesh:

Year:  2016        PMID: 27296314     DOI: 10.2174/1389450117666160613101413

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  24 in total

1.  Geometrical model of lobular structure and its importance for the liver perfusion analysis.

Authors:  Eduard Rohan; Jana Camprová Turjanicová; Václav Liška
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

2.  Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

3.  Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

4.  A radiomics-based model to classify the etiology of liver cirrhosis using gadoxetic acid-enhanced MRI.

Authors:  Aboelyazid Elkilany; Uli Fehrenbach; Timo Alexander Auer; Tobias Müller; Wenzel Schöning; Bernd Hamm; Dominik Geisel
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

5.  Study on clinical application of susceptibility weighted imaging ombined with diffusion weighted imaging in patients with Liver Cirrhosis complicated with small Hepatocellular Carcinoma.

Authors:  Zhi-Bo Hou; Fei Zhao; Bin Zhang; Chun-Zhu Zhang
Journal:  Pak J Med Sci       Date:  2021 May-Jun       Impact factor: 1.088

6.  Evolving strategies for liver fibrosis staging: Non-invasive assessment.

Authors:  Cristina Stasi; Stefano Milani
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

7.  miR-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis.

Authors:  Li Zhou; Shunai Liu; Ming Han; Yanhua Ma; Shenghu Feng; Jing Zhao; Hongping Lu; Xiaoxue Yuan; Jun Cheng
Journal:  Mol Ther Nucleic Acids       Date:  2017-11-24       Impact factor: 8.886

Review 8.  Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases.

Authors:  Chenxia Hu; Lingfei Zhao; Lanjuan Li
Journal:  J Mol Med (Berl)       Date:  2021-01-02       Impact factor: 4.599

Review 9.  The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review.

Authors:  Lei Zhang; Ke Pu; Xiaojun Liu; Sarah Da Won Bae; Romario Nguyen; Suyang Bai; Yi Li; Liang Qiao
Journal:  Front Med (Lausanne)       Date:  2021-07-01

10.  Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis.

Authors:  Kunihiro Hasegawa; Ryo Takata; Hiroki Nishikawa; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Int J Mol Sci       Date:  2016-09-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.